Compare Novavax Inc (NVAX) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Oatly Group AB - ADR — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Oatly Group AB - ADR trades at $12.53 (market cap $432.09M). The key difference: Novavax Inc is far larger — about 3.9× Oatly Group AB - ADR's market cap, and Novavax Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| NVAX | OTLY | |
|---|---|---|
Market Cap | $1.68B | $432.09M |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $18.09 |
52-Week Low | $6.22 | $8.03 |
Enterprise Value | $1.26B | $936.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
OTLY trades at $13.52, down 3.98% today, with a bullish technical signal supported by a recent golden cross and oversold RSI. Revenue growth improved to $862M in 2025, but net losses persist at -$153M, with negative cash flows. Analysts are mixed with 44% buy ratings, while the company raised its 2026 revenue outlook after Q2 results.
The outlook hinges on Oatly's path to profitability; accelerating revenue and margin improvements offer upside, but high debt and sustained losses pose significant risks. Investors should weigh operational progress against financial instability in a competitive plant-based market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
